### 1 **Relationship between acute SARS-CoV-2 viral clearance with Long COVID Symptoms: a**

- 2 **cohort study**  Carly Herbert<sup>1,2\*</sup>, Annukka A.R. Antar<sup>3</sup>, John Broach<sup>4</sup>, Colton Wright<sup>1</sup>, Pamela Stamegna<sup>1</sup>
- 3 Carly Herbert<sup>1,2°</sup>, Annukka A.R. Antar<sup>3</sup>, John Broach<sup>4</sup>, Colton Wright<sup>1</sup>, Pamela Stamegna<sup>1</sup>,<br>4 Katherine Luzuriaga<sup>2,5</sup>, Nathaniel Hafer<sup>2,5</sup>, David D McManus<sup>1,6,7</sup>, Yukari C Manabe<sup>3</sup>, Apurv<br>5 Soni<sup>1,6</sup> Soni $1,6,8$
- 5 6 <sup>1</sup> Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan<br>7 Medical School, Worcester, MA, USA 7 Medical School, Worcester, MA, USA<br>8 <sup>2</sup> University of Massachusetts Center fo
- <sup>2</sup>University of Massachusetts Center for Clinical and Translational Science, University of<br>9 Massachusetts Chan Medical School, Worcester, MA, USA 9 Massachusetts Chan Medical School, Worcester, MA, USA<br>10 <sup>3</sup>Division of Infectious Disease. Department of Medicine. Joh
- <sup>3</sup>Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of<br>11 Medicine, Baltimore, MD, USA
- 11 Medicine, Baltimore, MD, USA<br>12 <sup>4</sup>Department of Emergency Me <sup>4</sup> Department of Emergency Medicine, University of Massachusetts Chan Medical School,<br>13 Worcester, MA, USA
- 13 Worcester, MA, USA<br>14 <sup>5</sup>Program in Molecula
- <sup>5</sup>Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester,<br>15 MA, USA 15 MA, USA<br>16 <sup>6</sup>Division
- 16 <sup>6</sup>Division of Health System Science, Department of Medicine, University of Massachusetts Chan<br>17 Medical School, Worcester, MA, USA
- 17 Medical School, Worcester, MA, USA<br>18 <sup>7</sup> Division of Cardiology, Department of
- <sup>7</sup> Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical<br>19 School, Worcester, MA, USA
- 19 School, Worcester, MA, USA<br>20 <sup>8</sup>Department of Population an
- <sup>8</sup>Department of Population and Quantitative Health Sciences, University of Massachusetts Chan<br>21 Medical School, Worcester, MA, USA
- 21 Medical School, Worcester, MA, USA<br>22
- 
- 23<br>24 <sup>23</sup> Corresponding Author: Carly Herbert, Program in Digital Medicine, Department of Medicine,<br>24 University of Massachusetts Chan Medical School, Worcester, MA 01605,<br>25 e-mail: carly.herbert@umassmed.edu
- 24 University of Massachusetts Chan Medical School, Worcester, MA 01605,<br>25 e-mail: <u>carly.herbert@umassmed.edu</u><br>26
- e-mail: carly.herbert@umassmed.edu
- 
- $27$
- 
- 28
- 28
- 30
- $31$
- 
- 32

33 **Abstract:**  34 **Introduction:** The relationship between SARS-CoV-2 viral dynamics during acute infection and

- 35 the development of long COVID is largely unknown.<br>36 **Methods:** A total of 7361 asymptomatic community-dwelling people enrolled in the Test Us at
- 37 Home parent study between October 2021 and February 2022. Participants self-collected
- 38 anterior nasal swabs for SARS-CoV-2 RT-PCR testing every 24-48 hours for 10-14 days,
- 39 regardless of symptom or infection status. Participants who had no history of COVID-19 at
- 40 enrollment and who were subsequently found to have ≥1 positive SARS-CoV-2 RT-PCR test
- 41 during the parent study were recontacted in August 2023 and asked whether they had
- 42 experienced long COVID, defined as the development of new symptoms lasting 3 months or
- 43 experienced longer following SARS-CoV-2 infection. Participant's cycle threshold values were converted into
- 44 viral loads, and slopes of viral clearance were modeled using post-nadir viral loads. Using a log 45 binomial model with the modeled slopes as the exposure, we calculated the relative risk of
- 46 subsequently developing long COVID with 1-2 symptoms, 3-4 symptoms, or 5+ symptoms,
- 46 subsequently developing long COVID with 1-2 symptoms, 3-4 symptoms, or 5+ symptoms,<br>47 adjusting for age, number of symptoms, and SARS-CoV-2 variant. Adjusted relative risk (aF
- 47 adjusting for age, number of symptoms, and SARS-CoV-2 variant. Adjusted relative risk (aRR)<br>48 of individual long COVID symptoms based on viral clearance was also calculated.
- of individual long COVID symptoms based on viral clearance was also calculated.<br>49 Results: 172 participants were eligible for analyses, and 59 (34.3%) reported experiencing long
- 50 COVID. The risk of long COVID with 3-4 symptoms and 5+ symptoms increased by 2.44 times
- 51 (aRR: 2.44; 95% CI: 0.88-6.82) and 4.97 times (aRR: 4.97; 95% CI: 1.90-13.0) per viral load
- 52 slope-unit increase, respectively. Participants who developed long COVID had significantly
- 53 longer times from peak viral load to viral clearance during acute disease than those who never
- 54 developed long COVID (8.65 [95% CI: 8.28-9.01] vs. 10.0 [95% CI: 9.25-10.8]). The slope of
- 55 viral clearance was significantly positively associated with long COVID symptoms of fatigue 56 (aRR: 2.86; 95% CI: 1.22-6.69), brain fog (aRR: 4.94; 95% CI: 2.21-11.0), shortness of breath
- 56 (aRR: 2.86; 95% CI: 1.22-6.69), brain fog (aRR: 4.94; 95% CI: 2.21-11.0), shortness of breath<br>57 (aRR: 5.05; 95% CI: 1.24-20.6), and gastrointestinal symptoms (aRR: 5.46; 95% CI: 1.54-19.3) 57 (aRR: 5.05; 95% CI: 1.24-20.6), and gastrointestinal symptoms (aRR: 5.46; 95% CI: 1.54-19.3).<br><sup>5.9</sup> **Discussion:**

- 58 **Discussion:**<br>59 We observed that longer time from peak viral load to viral RNA clearance during acute COVID-
- 60 19 was associated with an increased risk of developing long COVID. Further, slower clearance
- 61 rates were associated with greater number of symptoms of long COVID. These findings suggest
- 61 rates were associated with greater number of symptoms of long COVID. These findings suggest<br>62 that early viral-host dynamics are mechanistically important in the subsequent development of 62 that early viral-host dynamics are mechanistically important in the subsequent development of<br>63 long COVID.
- 63 long COVID.
- 

### 65 65 **Key words:**

- 66 COVID-19, cycle threshold, SARS-CoV-2, viral clearance, long COVID, post-acute sequelae of 67<br>67 COVID-19 infection, PASC, viral persistence
- 67 COVID-19 infection, PASC, viral persistence<br>68
- 
- 68

70 **Introduction**: Long COVID, defined here as the presence of new or persistent symptoms for more than<br>72 three months after COVID-19 infection that cannot be explained by an alternative diagnosis, is 72 three months after COVID-19 infection that cannot be explained by an alternative diagnosis, is<br>73 thought to impact between 10%-30% of patients infected with SARS-COV-2.<sup>1-3</sup> Long COVID thought to impact between 10%-30% of patients infected with SARS-COV-2.<sup>1–3</sup> Long COVID<br>- . varies widely in its manifestation and severity; common symptoms include fatigue, brain fog,<br>75 and disordered sleep, and affected organ systems include cardiovascular, pulmonary, and 75 and disordered sleep, and affected organ systems include cardiovascular, pulmonary, and<br>76 neurologic, reviewed in Aiyegbusi et al.<sup>4</sup> Approximately one-fourth of individuals with long 76 neurologic, reviewed in Aiyegbusi et al.<sup>4</sup> Approximately one-fourth of individuals with long<br>-- 2008 Results in the state of the total to the second the second the state of the total to the state of the s 77 COVID report significant activity limitations, and long COVID has been found to have<br>78 detrimental effects on quality of life.<sup>5,6</sup> detrimental effects on quality of life.<sup>5,6</sup> 79 Currently, the mechanisms leading to long COVID remain unknown. One hypothesis is<br>80 that persistence of virus or viral antigen may lead to systemic and immunologic dysfunction.<sup>7-9</sup> that persistence of virus or viral antigen may lead to systemic and immunologic dysfunction.<sup>7-9</sup> 81 81 Specifically, studies have shown an association between long COVID and delayed clearance of 82 viral RNA during acute COVID-19.<sup>10,11</sup> persistent SARS-CoV-2 proteins in plasma.<sup>12</sup> viral RNA during acute COVID-19,<sup>10,11</sup> persistent SARS-CoV-2 proteins in plasma.<sup>12</sup> 82 monocytes,<sup>13</sup> and fecal matter.<sup>14,15</sup> However, previous studies have been limited by sample size<br>example in the size of the single size  $\frac{10,11}{2}$ and inconsistent testing frequency.<sup>10,11</sup> 85 Using a longitudinal cohort of ambulatory participants who were first infected with SARS-<br>86 CoV-2 between October 2021 and February 2022, we sought to determine if the rate of viral 86 CoV-2 between October 2021 and February 2022, we sought to determine if the rate of viral<br>87 clearance during acute infection is associated with the risk of subsequent development of lon 87 clearance during acute infection is associated with the risk of subsequent development of long<br>88 COVID. Given that long COVID may comprise two or more mechanistically distinct syndromes. 88 COVID. Given that long COVID may comprise two or more mechanistically distinct syndromes,<br>89 we investigated whether this association exists for some but not all long COVID symptoms. we investigated whether this association exists for some but not all long COVID symptoms.<br>90 Further, we explored whether specific symptoms displayed during acute SARS-CoV-2 infections. 90 Further, we explored whether specific symptoms displayed during acute SARS-CoV-2 infection<br>91 were associated with long COVID and the rate of viral clearance. were associated with long COVID and the rate of viral clearance.

92<br>93

**Methods:** 

94 **Study Population and Data Collection:** 

95 This study included participants from two longitudinal cohort studies, Test Us at Home and Test<br>96 Us at Home-Daily, which were funded by the National Institutes of Health's Rapid Acceleration 96 Us at Home-Daily, which were funded by the National Institutes of Health's Rapid Acceleration<br>97 of Diagnostics (RADx) program. All participants provided written consent to participate, and this 97 of Diagnostics (RADx) program. All participants provided written consent to participate, and this<br>98 study was approved by the WIRB-Copernicus Group (WCG) Institutional Review Board. 98 study was approved by the WIRB-Copernicus Group (WCG) Institutional Review Board.<br>99 Participants above the age of two vears from across the United States enrolled in these 99 Participants above the age of two years from across the United States enrolled in these studies<br>100 remotely between October 2021 and February 2022, and study materials were shipped to 100 remotely between October 2021 and February 2022, and study materials were shipped to<br>101 participant's homes. People were eligible to participate if they were asymptomatic on enrol 101 participant's homes. People were eligible to participate if they were asymptomatic on enrollment<br>102 and owned a smartphone. Communities with a high prevalence of SARS-CoV-2 were targeted 102 and owned a smartphone. Communities with a high prevalence of SARS-CoV-2 were targeted<br>103 for enrollment, to increase the likelihood of capturing transmission and the transition from 103 for enrollment, to increase the likelihood of capturing transmission and the transition from<br>104 negative to positive test results. Participants were asked to complete baseline demograph negative to positive test results. Participants were asked to complete baseline demographic<br>105 surveys and weekly symptom surveys, as well as collect anterior nasal swabs for SARS-Co\ 105 surveys and weekly symptom surveys, as well as collect anterior nasal swabs for SARS-CoV-2<br>106 antigen and RT-PCR testing every 48 hours over a 14-day period (Test Us at Home) or every 106 antigen and RT-PCR testing every 48 hours over a 14-day period (Test Us at Home) or every<br>107 24 hours over a 10-day period (Test Us at Home-Daily). Detailed information about the parent 24 hours over a 10-day period (Test Us at Home-Daily). Detailed information about the parent<br>108 studies can be found elsewhere.<sup>16</sup> studies can be found elsewhere.<sup>16</sup>

109 Participants 18 years of age or older with at least one positive PCR test during the original study<br>110 period were recontacted in August 2023, 18-22 months after initial SARS-CoV-2 infection. At 110 period were recontacted in August 2023, 18-22 months after initial SARS-CoV-2 infection. At<br>111 this follow-up, participants answered a 5-minute survey on persistent symptoms (from a list of 111 this follow-up, participants answered a 5-minute survey on persistent symptoms (from a list of<br>112 26, see Supplemental Appendix 1) and medical care utilization. Those participants who report 112 26, see Supplemental Appendix 1) and medical care utilization. Those participants who report<br>113 In previous SARS-CoV-2 infection on enrollment in the original study were included in this 113 no previous SARS-CoV-2 infection on enrollment in the original study were included in this<br>114 analysis (Figure 1). analysis (Figure 1).

115 **Measures:** 

116 **SARS-CoV-2 Molecular Testing:** Every 24 to 48 hours, participants collected a bilateral 117 anterior nasal swab, which was kept at room temperature and then mailed at room temperature<br>118 within 24 hours of collection to a central laboratory, Quest Diagnostics, for Roche Cobas RT-118 within 24 hours of collection to a central laboratory, Quest Diagnostics, for Roche Cobas RT-<br>119 PCR testing. Ct values for the E-gene from Roche Cobas 6800 SARS-CoV-2 RT-PCR were PCR testing. Ct values for the E-gene from Roche Cobas 6800 SARS-CoV-2 RT-PCR were

used in analyses to quantify viral load. Viral load was calculated as Ln(Viral Load)=((41.44-Ct<br>121 Value)/1.06), where increasing values represented increased viral load.<sup>17</sup> Peak viral load was 121 Value)/1.06), where increasing values represented increased viral load.<sup>17</sup> Peak viral load was  $\frac{1}{2}$ defined as the viral load at the time of the participant's nadir Ct value.<br>123 **Long COVID Outcomes:** In August 2023, participants were asked: "D

**Long COVID Outcomes:** In August 2023, participants were asked: "Did you have any<br>124 Symptoms lasting 3 months or longer that you did not have prior to having coronavirus 124 symptoms lasting 3 months or longer that you **did not have prior to having coronavirus** or<br>125 COVID-19?".<sup>5</sup> Participants who answered affirmatively were categorized as having had lo COVID-19?".<sup>5</sup> Participants who answered affirmatively were categorized as having had long<br>
2001/12001 126 COVID and were then asked what symptoms they experienced from among a list of 26<br>127 symptoms with a free text box to report more symptoms (Supplemental Appendix 1). W 127 symptoms with a free text box to report more symptoms (Supplemental Appendix 1). We<br>128 grouped long COVID symptoms by number of symptoms (1-2 long COVID symptoms, 3-4 128 grouped long COVID symptoms by number of symptoms (1-2 long COVID symptoms, 3-4<br>129 symptoms, or 5 or more symptoms). All participants were asked about their total number o 129 symptoms, or 5 or more symptoms). All participants were asked about their total number of<br>130 SARS-CoV-2 infections to date. SARS-CoV-2 infections to date.

131 **Survey Data from Original Study:** Number of vaccination doses, age, BMI, and comorbidities<br>132 were self-reported on enrollment. Participants were asked to indicate if they had the following were self-reported on enrollment. Participants were asked to indicate if they had the following<br>133 comorbidities: asthma, chronic kidney disease, COPD, cardiovascular disease, cancer, chroni 133 comorbidities: asthma, chronic kidney disease, COPD, cardiovascular disease, cancer, chronic<br>134 lung disease, depression, diabetes, hypertension, immunocompromising conditions, serious 134 lung disease, depression, diabetes, hypertension, immunocompromising conditions, serious 135 mental health disorders (bipolar or schizophrenia), sickle cell disease, substance use or alcohol<br>136 use disorders, or other. Participants self-reported acute symptoms (including fever, body aches, 136 use disorders, or other. Participants self-reported acute symptoms (including fever, body aches,<br>137 fatigue, rash, nausea, abdominal pain, diarrhea, loss of smell, runny nose, cough, headache, or 137 fatigue, rash, nausea, abdominal pain, diarrhea, loss of smell, runny nose, cough, headache, or<br>138 other) immediately prior to each swab collection using the study app. Symptoms were 138 other) immediately prior to each swab collection using the study app. Symptoms were<br>139 categorized as upper respiratory (loss of smell, runny nose, cough), systemic (fever, b 139 categorized as upper respiratory (loss of smell, runny nose, cough), systemic (fever, body<br>140 aches, fatigue, headache), or gastrointestinal symptoms (nausea, abdominal pain, diarrhea 140 aches, fatigue, headache), or gastrointestinal symptoms (nausea, abdominal pain, diarrhea).<br>141 Additionally, symptom reports were used to create a symptom score, which was the sum of 141 Additionally, symptom reports were used to create a symptom score, which was the sum of<br>142 symptoms the participant reported on each day. Each participant's SARS-CoV-2 variant was 142 symptoms the participant reported on each day. Each participant's SARS-CoV-2 variant was<br>143 determined via whole genome sequencing of their positive SARS-CoV-2 sample by amplicondetermined via whole genome sequencing of their positive SARS-CoV-2 sample by amplicon-

based next-generation sequencing on extracted RNA.<sup>18</sup> Non-sequenced positive samples<br>
(1990) 145 (n=20) were excluded in adjusted analyses.

146 **Analyses**:

147 Demographic characteristics were tabulated and stratified between participants with and without<br>148 Iong COVID. To calculate viral clearance, a linear mixed effects model with random slope and 148 long COVID. To calculate viral clearance, a linear mixed effects model with random slope and<br>149 random intercept was used to model log viral load values during the period of viral load decline 149 random intercept was used to model log viral load values during the period of viral load decline,<br>150 starting from the peak viral load. To calculate a slope of recovery, participants were required to 150 starting from the peak viral load. To calculate a slope of recovery, participants were required to<br>151 have two data points: 1) a peak viral load, and 2) one viral load of lesser value occurring after 151 have two data points: 1) a peak viral load, and 2) one viral load of lesser value occurring after<br>152 the peak viral load. Log viral load follows a linear pattern over time, which accounts for the the peak viral load. Log viral load follows a linear pattern over time, which accounts for the<br>153 exponential phases of viral decline during recovery.<sup>19,20</sup> Modeled slopes were calculated for exponential phases of viral decline during recovery.<sup>19,20</sup> Modeled slopes were calculated for  $(1, 1, 1)$ each participant (Supplemental Figure 1). Using a log binomial model with the modeled slopes<br>155 as the exposure, we calculated the relative risk of subsequently developing long COVID with 1as the exposure, we calculated the relative risk of subsequently developing long COVID with 1-2<br>156 symptoms, 3-4 symptoms, or 5+ symptoms. To assess whether the relationship between viral 156 symptoms, 3-4 symptoms, or 5+ symptoms. To assess whether the relationship between viral<br>157 clearance and long COVID was consistent between men and women, we used a log binomial clearance and long COVID was consistent between men and women, we used a log binomial<br>158 model with an interaction term between slope and biological sex, and nonlinear combinations 158 model with an interaction term between slope and biological sex, and nonlinear combinations of<br>159 predictions were used to quantify the differences by BMI and sex and to calculate the 159 predictions were used to quantify the differences by BMI and sex and to calculate the<br>160 accompanying 95% confidence intervals. We also calculated the relative risk of slope 160 accompanying 95% confidence intervals. We also calculated the relative risk of slope of viral<br>161 clearance on each long COVID symptom that received more than 5 affirmative responses and 161 clearance on each long COVID symptom that received more than 5 affirmative responses and<br>162 displayed these results as a forest plot. We evaluated maximum number of symptoms during 162 displayed these results as a forest plot. We evaluated maximum number of symptoms during<br>163 acute infection, number of infections, vaccination status, age, comorbidities, BMI, sex, and 163 acute infection, number of infections, vaccination status, age, comorbidities, BMI, sex, and<br>164 SARS-CoV-2 variant as confounders, and included variables based on a 10% change-in-SARS-CoV-2 variant as confounders, and included variables based on a 10% change-in-<br>165 estimate criterion.<sup>21</sup> Maximum symptoms, age, and variant were determined to be confour 165 estimate criterion.<sup>21</sup> Maximum symptoms, age, and variant were determined to be confounders 166 using this criterion and included as confounders in the adjusted models. To facilitate<br>167 interpretation, we also displayed slopes in terms of days to clearance, assuming inte 167 interpretation, we also displayed slopes in terms of days to clearance, assuming intercepts (i.e., 168 maximum viral load) at the  $25^{th}$ , 50<sup>th</sup>, and 75<sup>th</sup> percentile. Estimates and 95% confidence 168 maximum viral load) at the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> percentile. Estimates and 95% confidence 168 per person.

169 intervals were generated through the bootstrap methodology to incorporate measures of<br>170 uncertainty. Clearance was defined as a Ct value ≥40 which is the limit of detection (i.e., 170 uncertainty. Clearance was defined as a Ct value ≥40 which is the limit of detection (i.e., log<br>171 viral load of 3.90). viral load of 3.90).

172 Lastly, we analyzed participant-reported symptoms recorded during acute infection and<br>173 Calculated relative risk of subsequent development of long COVID for each individual ac calculated relative risk of subsequent development of long COVID for each individual acute<br>174 symptom, acute symptom category (upper respiratory, gastrointestinal, or systemic), and 174 symptom, acute symptom category (upper respiratory, gastrointestinal, or systemic), and<br>175 cumulative number of acute symptoms. Confounders were similarly determined using a 1 175 cumulative number of acute symptoms. Confounders were similarly determined using a 10%<br>176 change-in-estimate criterion, and models were adjusted for age and variant. We conducted 176 change-in-estimate criterion, and models were adjusted for age and variant. We conducted<br>177 sensitivity analyses analyzing participants who reported just one total SARS-CoV-2 infection 177 sensitivity analyses analyzing participants who reported just one total SARS-CoV-2 infection as<br>178 of August 2023. All analyses were conducted using STATA 17.0. of August 2023. All analyses were conducted using STATA 17.0.

#### 179 **Results:**

#### 180 **Participant Characteristics**

181 Of the 7988 participants enrolled in parent studies Test Us at Home and Test Us at Home Daily,<br>182 451 participants tested positive for SARS-CoV-2 by RT-PCR during the parent study and were 182 451 participants tested positive for SARS-CoV-2 by RT-PCR during the parent study and were<br>183 18 years or older, and thus eligible for the long COVID survey in August 2023. In total, 200 183 18 years or older, and thus eligible for the long COVID survey in August 2023. In total, 200<br>184 participants (44.3%) responded to the long COVID survey. We limited analyses to the 172 184 participants (44.3%) responded to the long COVID survey. We limited analyses to the 172<br>185 participants whose first known infection with SARS-CoV-2 occurred during the parent study participants whose first known infection with SARS-CoV-2 occurred during the parent study<br>186 – period (Fiqure 1). Among 172 respondents, 59 (34.3%) reported having had long COVID, h 186 period (**Figure 1**). Among 172 respondents, 59 (34.3%) reported having had long COVID, here<br>187 defined as the presence of symptoms for three months or longer following COVID-19. defined as the presence of symptoms for three months or longer following COVID-19. 188 In total, 128 of the 172 (74.4%) of participants were women, and the median age was 37 (IQR,<br>189 32-44). The majority of participants (62.2%) had no comorbidities, while 11.0% of participants 189 32-44). The majority of participants (62.2%) had no comorbidities, while 11.0% of participants<br>190 had 2+ comorbidities (**Table 1**). Among the 59 participants with long COVID, 8 (13.6%) visited 190 had 2+ comorbidities (**Table 1**). Among the 59 participants with long COVID, 8 (13.6%) visited 191 the emergency room during their SARS-CoV-2 infection, compared to just 1 participant (0.88%)<br>192 vithout long COVID. Only one participant was hospitalized during their acute SARS-CoV-2 without long COVID. Only one participant was hospitalized during their acute SARS-CoV-2

193 infection. As of August 2023, 71.7% of participants who never had long COVID reported having 194 just one SARS-CoV-2 infection, while 40.7% of those with long COVID reported having just one<br>195 SARS-CoV-2 infection. In our sample, 128 participants (74.4%) had their peak viral load and a 195 SARS-CoV-2 infection. In our sample, 128 participants (74.4%) had their peak viral load and a<br>196 prior lower viral load captured during the study period. prior lower viral load captured during the study period.

# 197 **Association between long COVID and Slope of Viral Clearance**<br>198 The slope of viral clearance was higher (i.e., flatter) among participa

198 The slope of viral clearance was higher (i.e., flatter) among participants with 5+ long COVID<br>199 symptoms compared to those with 3-4 long COVID symptoms, 1-2 long COVID symptoms, c 199 symptoms compared to those with 3-4 long COVID symptoms, 1-2 long COVID symptoms, or<br>199 those without long COVID (Fiqure 2a, Fiqure 2b). Slope of viral clearance had no association 200 those without long COVID (**Figure 2a, Figure 2b**). Slope of viral clearance had no association<br>201 with risk of long COVID with only 1-2 symptoms (Table 2). However, the risk of long COVID wit 201 with risk of long COVID with only 1-2 symptoms (**Table 2**). However, the risk of long COVID with 202 3-4 symptoms was 2.44 times higher (Adjusted RR (aRR): 2.44; 95% CI: 0.88-6.82) in models<br>203 adjusted for age, maximum acute symptoms, and SARS-CoV-2 variant per slope-unit increase adjusted for age, maximum acute symptoms, and SARS-CoV-2 variant per slope-unit increase<br>204 (Table 2). This association was strongest among participants with 5+ long COVID symptoms, 204 (**Table 2**). This association was strongest among participants with 5+ long COVID symptoms, where a slope-unit increase was associated with nearly five-times higher risk of long COVID<br>206 with 5+ symptoms (aRR: 4.97; 95% CI: 1.90-12.98). The interaction term for biological sex w 206 with 5+ symptoms (aRR: 4.97; 95% CI: 1.90-12.98). The interaction term for biological sex was<br>207 statistically significant (p=0.023), and we observed that the relationship between slope and long 207 statistically significant (p=0.023), and we observed that the relationship between slope and long<br>208 COVID was not consistent between men and women. While the probability of long COVID 208 COVID was not consistent between men and women. While the probability of long COVID<br>209 increased as slope decreased among females, the same relationship was not observed an 209 increased as slope decreased among females, the same relationship was not observed among<br>210 men (**Figure 3**). men (**Figure 3**).

211 For participants who never had long COVID, the time from maximum viral load to viral clearance<br>212 during the first SARS-CoV-2 infection was 8.65 days (95% CI: 8.28-9.01), assuming a nadir Ct 212 during the first SARS-CoV-2 infection was 8.65 days (95% CI: 8.28-9.01), assuming a nadir Ct<br>213 value of 24.2, which was the median among this population (Figure 2c, Supplemental Table 213 value of 24.2, which was the median among this population (**Figure 2c, Supplemental Table**  214 **1**). Participants with long COVID had significantly longer times to viral clearance in their first<br>215 SARS-CoV-2 infection than those without long COVID (No long COVID: 8.65 (95% CI: 8.28-215 SARS-CoV-2 infection than those without long COVID (No long COVID: 8.65 (95% CI: 8.28- 216 9.01); Long COVID: 10.0 (95% CI: 9.25-10.8)). For participants with more than three long<br>217 COVID symptoms, time to clearance was highest, at 11.7 days (95% CI: 10.8-12.6). For 217 COVID symptoms, time to clearance was highest, at 11.7 days (95% CI: 10.8-12.6). For

participants with peak viral loads in the 25<sup>th</sup> percentile (nadir Ct value=28.6), time to clearance<br>218 **percention** was lower, and ranged from 5.70 days (95% CI: 5.46-5.94) among those without long COVID to<br>220 7.71 days (95% CI: 7.11-8.32) among those with more than three long COVID symptoms. For 220 7.71 days (95% CI: 7.11-8.32) among those with more than three long COVID symptoms. For<br>221 participants with peak viral loads in the 75<sup>th</sup> percentile (nadir Ct value=21.4), time to clearance participants with peak viral loads in the 75<sup>th</sup> percentile (nadir Ct value=21.4), time to clearance<br>
221 participants with peak viral loads in the 75<sup>th</sup> percentile (nadir Ct value=21.4), time to clearance was higher, and ranged from 10.5 days (95% CI: 10.0-10.9) among those without long COVID<br>223 U 14.2 days (95% CI: 13.0-15.3) among those with three or more long COVID symptoms. to 14.2 days (95% CI: 13.0-15.3) among those with three or more long COVID symptoms.

## 224 **Relationship between Slope of Viral Clearance and Specific Long COVID Symptoms**

225 Slope of viral clearance was significantly positively associated with long COVID symptoms of<br>226 fatigue (aRR: 2.86; 95% CI: 1.22-6.69), brain fog (aRR: 4.94; 95% CI: 2.21-11.0), shortness o

226 fatigue (aRR: 2.86; 95% CI: 1.22-6.69), brain fog (aRR: 4.94; 95% CI: 2.21-11.0), shortness of

breath (aRR: 5.05; 95% CI: 1.24-20.6), and gastrointestinal symptoms (aRR: 5.46; 95% CI:<br>228 1.54-19.3) (Figure 4). In other words, for each unit increase in slope, the risk of long COVID

228 1.54-19.3) (**Figure 4**). In other words, for each unit increase in slope, the risk of long COVID

with fatigue increased by 2.86 times. We did not observe a significant association between<br>230 Slope of viral clearance and long COVID symptoms of cough, change in taste or smell, men

230 slope of viral clearance and long COVID symptoms of cough, change in taste or smell, mental<br>231 health symptoms, or hair loss.

health symptoms, or hair loss.

## 232 **Acute COVID-19 Symptoms and Risk of long COVID**

Each additional symptom reported during the acute COVID-19 infection period was associated<br>234 with a 21% (95% CI: 1.03-1.43) and 24% (95% CI: 1.11-1.39) increased risk of long COVID with with a 21% (95% CI: 1.03-1.43) and 24% (95% CI: 1.11-1.39) increased risk of long COVID with<br>235 3-4 symptoms and 5+ symptoms, respectively (**Table 3**). No acute symptoms were associated 235 3-4 symptoms and 5+ symptoms, respectively (**Table 3**). No acute symptoms were associated 236 with increased risk of long COVID with 1-2 symptoms. We observed that the acute symptoms of<br>237 abdominal pain (aRR: 5.41; 95% CI: 2.44-12.0), nausea (aRR: 3.01; 95% CI: 1.31-6.89), and 237 abdominal pain (aRR: 5.41; 95% CI: 2.44-12.0), nausea (aRR: 3.01; 95% CI: 1.31-6.89), and 238 body aches (aRR: 2.58; 95% CI: 1.26-5.30) during SARS-CoV-2 infection were the three<br>239 individual symptoms most strongly associated with long COVID (Figure 5). When looking 239 individual symptoms most strongly associated with long COVID (Figure 5). When looking at<br>240 symptom groupings, upper respiratory symptoms during acute infection, including loss of sm 240 symptom groupings, upper respiratory symptoms during acute infection, including loss of smell,<br>241 runny nose, and cough, were not associated with an increased risk of long COVID, regardless zum 241 runny nose, and cough, were not associated with an increased risk of long COVID, regardless<br>242 of the number of symptoms. Gastrointestinal symptoms were associated with 3.91 times the rist 242 of the number of symptoms. Gastrointestinal symptoms were associated with 3.91 times the risk

of long COVID with 5+ symptoms after adjusting for age, BMI, and variant (aRR: 3.91, 95% CI:<br>244 1.72-8.92); however, gastrointestinal symptoms were not significantly associated with an 244 1.72-8.92); however, gastrointestinal symptoms were not significantly associated with an<br>245 increased risk of long COVID with 3-4 symptoms. Furthermore, systemic symptoms were 245 increased risk of long COVID with 3-4 symptoms. Furthermore, systemic symptoms were<br>246 associated with 4.16 times (95% CI: 1.63-10.6) the risk of long COVID with 3-4 symptoms 246 associated with 4.16 times (95% CI: 1.63-10.6) the risk of long COVID with 3-4 symptoms and<br>247 5.52 times (95% CI: 2.02-15.0) the risk of long COVID with 5+ symptoms. These results were 247 5.52 times (95% CI: 2.02-15.0) the risk of long COVID with 5+ symptoms. These results were<br>248 consistent when restricting to patients who reported just one SARS-CoV-2 infection as of consistent when restricting to patients who reported just one SARS-CoV-2 infection as of<br>249 August 2023 (Supplemental Table 2). 249 August 2023 (**Supplemental Table 2**).

#### 250 **Discussion**

251 Using longitudinal data collected from participants during their acute SARS-CoV-2 infections, we<br>252 report that longer time to clearance during acute COVID-19 is associated with an increased risk 252 report that longer time to clearance during acute COVID-19 is associated with an increased risk<br>253 of long COVID, and this relationship is stronger with increasing numbers of long COVID 253 of long COVID, and this relationship is stronger with increasing numbers of long COVID<br>254 symptoms. This study is unique in its ability to pair acute infection dynamics with long ter 254 symptoms. This study is unique in its ability to pair acute infection dynamics with long term<br>255 outcomes of COVID-19 infection; we offer a prospective, longitudinal examination of infectio 255 outcomes of COVID-19 infection; we offer a prospective, longitudinal examination of infection<br>256 trajectories and their relationship with long COVID. Our large sample size includes participants 256 trajectories and their relationship with long COVID. Our large sample size includes participants<br>257 from across the United States and includes infections with both the Omicron and Delta SARS-257 from across the United States and includes infections with both the Omicron and Delta SARS-<br>258 CoV-2 variants. Further, the frequent sample collection during the acute SARS-CoV-2 infectior 258 CoV-2 variants. Further, the frequent sample collection during the acute SARS-CoV-2 infection<br>259 period allowed us to model viral clearance with high granularity. period allowed us to model viral clearance with high granularity.

## 260 **Delayed SARS-CoV-2 Viral Clearance and Long COVID**

261 Most studies of clinical viral dynamics have occurred in hospital settings; however, nearly 81%<br>262 of SARS-CoV-2 infections are mild to moderate and self-resolving.<sup>22</sup> Additionally, the majority o 262 of SARS-CoV-2 infections are mild to moderate and self-resolving.<sup>22</sup> Additionally, the majority of 263 Iong COVID patients were not hospitalized for COVID-19.<sup>23</sup> Therefore, our study of adults with 264 mild to moderate infections offers an important lens into the longitudinal course of SARS-CoV-2<br>265 infections occurring outside the clinical setting. Among ambulatory outpatients with mild to 265 infections occurring outside the clinical setting. Among ambulatory outpatients with mild to<br>266 moderate SARS-CoV-2 infections, Antar et al. also found that delayed time to clearance 266 moderate SARS-CoV-2 infections, Antar et al. also found that delayed time to clearance<br>267 (defined as viral clearance >28 days after symptom onset) was associated with long CO\ 267 (defined as viral clearance >28 days after symptom onset) was associated with long COVID

268 with brain fog and muscle pain.<sup>10</sup> However, they did not find a statistically significant association<br>2004 Hotel Britannic COVID 269 between viral clearance and other long COVID symptoms, likely due to sample size and less<br>270 frequent sampling. Our larger sample size, more frequent sampling, and inclusion of participa 270 frequent sampling. Our larger sample size, more frequent sampling, and inclusion of participants<br>271 who went from SARS-CoV-2 negative to positive, allowed us to use a continuous measure to 271 who went from SARS-CoV-2 negative to positive, allowed us to use a continuous measure to<br>272 show that time to clearance was longer among those with long COVID than those without long 272 show that time to clearance was longer among those with long COVID than those without long<br>273 COVID, rather than categorizing clearance at 28 days. Similarly, we found a strong association 273 COVID, rather than categorizing clearance at 28 days. Similarly, we found a strong association<br>274 between viral clearance and brain fog, as well as GI symptoms and shortness of breath. 274 between viral clearance and brain fog, as well as GI symptoms and shortness of breath.<br>275 Another study of participants with mild to moderate SARS-CoV-2 infections also found are 275 Another study of participants with mild to moderate SARS-CoV-2 infections also found an<br>276 association between long COVID and higher peak viral loads, as well as duration of viral 276 association between long COVID and higher peak viral loads, as well as duration of viral<br>277 shedding.<sup>11</sup> This study included primarily participants infected with non-Omicron variants. shedding.<sup>11</sup> 277 This study included primarily participants infected with non-Omicron variants, and 278 65% of their participants were unvaccinated. Therefore, it is notable that we found that time to<br>279 viral clearance had an association with long COVID in our population too, which included 279 viral clearance had an association with long COVID in our population too, which included<br>280 maiority Omicron infections and vaccinated participants. Additionally, our study had >50% 280 majority Omicron infections and vaccinated participants. Additionally, our study had >50% more<br>281 participants, and we were uniquely able to document the transition from negative to positive, 281 participants, and we were uniquely able to document the transition from negative to positive,<br>282 while Lu et al. enrolled participants within 5 days of their first positive test. while Lu et al. enrolled participants within 5 days of their first positive test.

283 Our results add to evidence showing an association between delayed viral clearance<br>284 and long COVID.<sup>10,11</sup> Delaved viral clearance mav be related to long COVID through several 284 and long COVID.<sup>10,11</sup> Delayed viral clearance may be related to long COVID through several<br>285 December 2002 December 2003 December 2003 December 2003 December 2003 December 2003 December 2003 December 2 285 mechanisms. First, delayed immune response, specifically secretory IgA, to SARS-CoV-2 may<br>286 cause delayed viral clearance.<sup>24</sup> This may occur due to underlying immune dysfunction caused 286 cause delayed viral clearance.<sup>24</sup> This may occur due to underlying immune dysfunction caused<br>225 This may be a strong that the strong test of the strong test of the strong test of the strong test of the strong test o 287 by autoimmune or comorbid conditions, which themselves may be associated with long<br>288 COVID.<sup>25,26</sup> Furthermore, our finding is consistent with the finding that vaccination provide 288 COVID.<sup>25,26</sup> Furthermore, our finding is consistent with the finding that vaccination provides 289 partial protection from long COVID.<sup>25</sup> In this case, vaccination may enable an infected individual protection from long COVID.<sup>25</sup> In this case, vaccination may enable an infected individual 290 to mount a faster or more effective immune response to clear viral RNA, and in turn this faster<br>291 clearance is associated with decreased risk for long COVID.<sup>27–30</sup> Additionally, delayed viral clearance is associated with decreased risk for long COVID.<sup>27–30</sup> Additionally, delayed viral<br>2008 **Additionally**, delayed viral 292 clearance may in itself *cause* immune dysfunction through chronic immune activation, including

293 lymphocyte overstimulation, leading to inflammatory responses and potential cross-reactive<br>294 immune responses.<sup>31–33</sup> Whether the immune dysfunction underlies or causes the delayed v 294 immune responses.<sup>31–33</sup> Whether the immune dysfunction underlies or causes the delayed viral<br>2005 **10 August 2006** 295 clearance is still unknown; however, this heightened inflammatory state may possibly delay 296 healing from the acute infection, trigger autoimmunity, or cause organ damage, all resulting in 297 long-term symptoms. Therefore, the speed and functionality of the immune response<br>298 responsible for clearing virus from the upper respiratory tract may either directly impa zerations are responsible for clearing virus from the upper respiratory tract may either directly impact long<br>299 COVID risk or be associated with other dysfunction or damage related to long COVID, and 299 COVID risk or be associated with other dysfunction or damage related to long COVID, and<br>300 Fesult in serious implications for long-term symptom resolution.<sup>31,32</sup> result in serious implications for long-term symptom resolution.<sup>31,32</sup>

301 We also observed that the association between viral clearance and long COVID differed<br>302 between men and women. It appeared the relationship between viral clearance and long 302 between men and women. It appeared the relationship between viral clearance and long COVID<br>303 was stronger among women, compared to men. It is well documented that men comprised more was stronger among women, compared to men. It is well documented that men comprised more<br>304 COVID-19-related deaths and hospitalizations. compared to women. and evidence has shown 304 COVID-19-related deaths and hospitalizations, compared to women, and evidence has shown<br>305 higher viral loads among men compared to women.<sup>34,35</sup> However, women are more likely than higher viral loads among men compared to women.<sup>34,35</sup> However, women are more likely than<br>eses men to report long COVID.1,36 306 Men and women have been observed to have different responses to viral infection, with men having less robust innate immune responses than women.<sup>37,38</sup> This<br>contract the material of the state of the state of the contract the state of the state of the state of the sta 308 may indicate that the immune dysfunction leading to long COVID is mediated by sex-specific<br>309 factors: however, this observation may also be due to the limited number of men in our study 309 factors; however, this observation may also be due to the limited number of men in our study<br>310 cohort. Therefore, further sex-specific analyses are necessary to further evaluate this finding. cohort. Therefore, further sex-specific analyses are necessary to further evaluate this finding.

#### 311 **Association between acute symptoms and Long COVID**

312 We found that certain symptoms during acute COVID-19 infection were associated with a higher<br>313 Fisk of long COVID than others.<sup>39,40</sup> Abdominal pain during acute COVID-19 infection was the risk of long COVID than others.<sup>39,40</sup> Abdominal pain during acute COVID-19 infection was the<br>experiments of the contract of the 314 single symptom most significantly associated with future risk of long COVID. Gastrointestinal<br>315 symptoms are reported in 15-50% of acute COVID-19 infections, and SARS-CoV-2 RNA, 315 symptoms are reported in 15-50% of acute COVID-19 infections, and SARS-CoV-2 RNA,<br>316 antigen, and virions have all been identified in the GI tract of COVID-19 patients.<sup>41–43</sup> Furth antigen, and virions have all been identified in the GI tract of COVID-19 patients.<sup>41–43</sup> Further, 316 F 317 previous studies have indicated that SARS-CoV-2 clearance in respiratory tissues may be more

rapid than clearance within gastrointestinal tissues.<sup>14</sup> Fecal shedding of RNA has been<br>2008 Fecal shedding of RNA has been 319 correlated with a variety of GI symptoms, including abdominal pain. It may be that abdominal<br>320 pain is a crude indicator of viral dissemination outside the upper respiratory tract, and viral 320 pain is a crude indicator of viral dissemination outside the upper respiratory tract, and viral<br>321 dissemination is associated with long COVID. However, viral RNA in the GI tract has been dissemination is associated with long COVID. However, viral RNA in the GI tract has been<br>322 found in patients with and without long COVID.<sup>14</sup> The GI tract is highly immunoreactive, and found in patients with and without long COVID.<sup>14</sup> The GI tract is highly immunoreactive, and it is<br>case the distribution of the contract of the CADCO of the CH contract of the contract of the contract of the con 323 hypothesized that prolonged exposure to SARS-CoV-2 in the GI tract may have immunological<br>324 implications and contribute to many common long COVID symptoms. implications and contribute to many common long COVID symptoms.

## 325 **Limitations and strengths**

326 This study has several limitations. The parent study period was 14 days; therefore, duration of<br>327 infection was calculated through modeled estimates, rather than observed clearance. While we 327 infection was calculated through modeled estimates, rather than observed clearance. While we<br>328 classified long COVID by number of symptoms reported, we did not consider the severity of classified long COVID by number of symptoms reported, we did not consider the severity of<br>329 each symptom. We were also limited in our ability to perform further subgroup analyses on s each symptom. We were also limited in our ability to perform further subgroup analyses on sex<br>330 and long COVID symptoms due to sample size. Previous infections were self-reported: 330 and long COVID symptoms due to sample size. Previous infections were self-reported;<br>331 therefore, it is possibly participants were unknowingly infected with SARS-CoV-2 prior to 331 therefore, it is possibly participants were unknowingly infected with SARS-CoV-2 prior to the<br>332 infection documented during the study period. There is also the potential for recall bias for lor 332 infection documented during the study period. There is also the potential for recall bias for long<br>333 COVID symptoms. Further, the FDA granted an EUA for Paxlovid for the treatment of 333 COVID symptoms. Further, the FDA granted an EUA for Paxlovid for the treatment of<br>334 individuals with mild to moderate COVID-19 at risk of developing severe COVID-19 on 334 individuals with mild to moderate COVID-19 at risk of developing severe COVID-19 on 335 December 22, 2021, which occurred in the middle of our study. However, outside of long-term<br>336 care settings, use of Paxlovid in January and February 2022 was very low in the United States care settings, use of Paxlovid in January and February 2022 was very low in the United States,<br>337 vith less than 22 prescriptions and less than 40 prescriptions per 100.000 people <65 years old with less than 22 prescriptions and less than 40 prescriptions per 100,000 people <65 years old<br>338 and >65 years old, respectively.<sup>44</sup> Lastly, as of December 2022, more than 50% of COVID-19 and >65 years old, respectively.<sup>44</sup> Lastly, as of December 2022, more than 50% of COVID-19<br>cos cases in the United States were reinfections, and individual's cumulative exposure to the virus<br>340 continues to increase with the mutation and spread of the Omicron variant.<sup>45</sup> Understanding the continues to increase with the mutation and spread of the Omicron variant.<sup>45</sup> Understanding the viral dynamics from an individual's first COVID-19 infection can form a baseline to enhance our<br>342 understanding of the relationship between subsequent infections on the risk of long COVID.<sup>46</sup> understanding of the relationship between subsequent infections on the risk of long COVID.<sup>46</sup>

- 343 However, future studies are needed to explore the impact of reinfection on viral clearance and<br>344 the connection with long COVID.
- the connection with long COVID.

## 345 **Conclusion**

- 346 We observed that slower rates of viral RNA clearances during acute COVID-19 were associated<br>347 with an increased risk of developing long COVID. Further, slower clearance rates were
- 347 with an increased risk of developing long COVID. Further, slower clearance rates were<br>348 associated with a greater number of long COVID symptoms. These findings suggest tha
- 348 associated with a greater number of long COVID symptoms. These findings suggest that early<br>349 viral-host dynamics are mechanistically important in the subsequent development of long
- 349 viral-host dynamics are mechanistically important in the subsequent development of long<br>350 COVID.
- COVID.

# 352<br>353

**Potential Conflicts of Interest**: DDM reports consulting and research grants from Bristol-Myers<br>354 Squibb and Pfizer, consulting and research support from Fitbit, consulting and research support<br>355 from Flexcon, researc 355 from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial<br>356 research support from Apple Computer, consulting/other support from Heart Rhythm Society. 356 research support from Apple Computer, consulting/other support from Heart Rhythm Society.<br>357 YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-357 YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-<br>358 related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives 358 related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives<br>359 funding support to Johns Hopkins University from miDiagnostics. KL receives research fun 359 funding support to Johns Hopkins University from miDiagnostics. KL receives research funding<br>360 from Moderna and has consulted for Gilead. Additional authors declare no financial or non-359 funding support to Johns Hopkins University from miDiagnostics. KL receives research funding<br>360 from Moderna and has consulted for Gilead. Additional authors declare no financial or non-<br>000 360 from Moderna and has consulted for Gilead. Additional authors declare no financial or non-<br>361 financial competing interests.<br>- - -361 financial competing interests.<br>362<br>363 Patient Consent Statement: All participants provided written consent for this study. This study

363<br>364 363 **Patient Consent Statement:** All participants provided written consent for this study. This study 364 was approved by the WIRB-Copernicus Group (WCG) Institutional Review Board (20214875).<br>365 **Funding Statement**: This study was funded by the NIH RADx Tech program under

- 
- 365 **Funding Statement**: This study was funded by the NIH RADx Tech program under<br>366 3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this<br>367 manuscript are those of the authors and do not necessa
- 367 manuscript are those of the authors and do not necessarily represent the views of the National<br>368 Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood
- 368 Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood<br>369 Institute: the National Institutes of Health; the Food and Drug Administration, or the U.S. 368 Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood<br>369 Institute; the National Institutes of Health; the Food and Drug Administration, or the U.S.
- 369 Institute; the National Institutes of Health; the Food and Drug Administration, or the U.S.<br>370 Department of Health and Human Services.
- 370 Department of Health and Human Services.<br>371 **Author Contributions:** YCM, AA, AS, CH c
- 371 **Author Contributions:** YCM, AA, AS, CH conceptualized the research question. CH, AS, YCM, 372 AA contributed to design of methodology. AS, CH, CW, JB, PS contributed to data collection<br>373 and curation. CH conducted f
- 
- 373 and curation. CH conducted formal analysis and wrote the original draft. KL, DDM, NH, YCM, 374 AA provided supervision. CW and PS provided administrative support. DM, JB, AS, NH, KL
- 374 AA provided supervision. CW and PS provided administrative support. DM, JB, AS, NH, KL<br>375 contributed to funding acquisition. All authors contributed to reviewing and editing the 374 AA provided supervision. CW and PS provided administrative support. DM, JB, AS, NH, KL<br>375 contributed to funding acquisition. All authors contributed to reviewing and editing the
- 375 contributed to funding acquisition. All authors contributed to reviewing and editing the<br>376 manuscript.
- 

376 manuscript.<br>377 Acknowledgment: We are grateful to our study participants and to our collaborators from the

378 National Institute of Health (NIBIB and NHLBI) who provided scientific input into the design of<br>379 this study and interpretation of our results but could not formally ioin as co-authors due to

379 this study and interpretation of our results but could not formally join as co-authors due to<br>380 institutional policies and to the Food and Drug Administration (Office of In Vitro Diagnostic

- 380 institutional policies and to the Food and Drug Administration (Office of In Vitro Diagnostics and 381 Radiological Health) for their involvement in the primary TUAH study. We received meaningful
- 381 Radiological Health) for their involvement in the primary TUAH study. We received meaningful<br>382 contributions from Drs. Bruce Tromberg, Jill Heemskerk, Felicia Qashu, Dennis Buxton, Erin

382 contributions from Drs. Bruce Tromberg, Jill Heemskerk, Felicia Qashu, Dennis Buxton, Erin<br>383 Iturriaga, Jue Chen, Andrew Weitz, and Krishna Juluru. We are thankful to county health

- 383 Iturriaga, Jue Chen, Andrew Weitz, and Krishna Juluru. We are thankful to county health<br>384 departments across the country who helped with recruitment for this siteless study by spr 383 Iturriaga, Jue Chen, Andrew Weitz, and Krishna Juluru. We are thankful to county health<br>384 departments across the country who helped with recruitment for this siteless study by spr 384 departments across the country who helped with recruitment for this siteless study by spreading<br>385 the word in their networks.
- 385 the word in their networks.

- 1. Long COVID Household Pulse Survey COVID-19. Published November 6, 2023. Accessed November
- 2. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet Lond Engl. 2022;400(10350):452-461. doi:10.1016/S0140-6736(22)01214-4 Lancet Lond Engl. 2022;400(10350):452-461. doi:10.1016/S0140-6736(22)01214-4
- 3. Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and Correlates of Long COVID Symptoms<br>Among US Adults. JAMA Netw Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen. 2022.38804
- 4. Aivegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a  $\frac{1}{4}$  are Sec, Med. 2021;114(9):428-442. doi:10.1177/01410768211032850 review. J R Soc Med. 2021;114(9):428-442. doi:10.1177/01410768211032850<br>-<br>-
- 5. Ford ND. Long COVID and Significant Activity Limitation Among Adults, by Age United States, June 1–13, 2022, to June 7–19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7232a3
- 6. Walker S, Goodfellow H, Pookarnjanamorakot P, et al. Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open. 2023;13(6):e069217. doi:10.1136/bmjopen-2022-069217 observational study. BMJ Open. 2023;13(6):e069217. doi:10.1136/bmjopen-2022-069217
- 1. Brownsend P, Casari B, Casari G, Townsend P, Casari G, Townsend COVID-19. Nat Med. 2022;28(5):879-882. doi:10.1038/s41591-022-01766-7 disorders beyond COVID-19. Nat Med. 2022;28(5):879-882. doi:10.1038/s41591-022-01766-7
- (PASC). Nat Immunol. 2023;24(10):1616-1627. doi:10.1038/s41590-023-01601-2 (PASC). Nat Immunol. 2023;24(10):1616-1627. doi:10.1038/s41590-023-01601-2
- 9. Particing, McCorkell L, Vogel III, Vogel III, Long Corkell Ling, McChanisms and Tecommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-008 recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
- 10. Antar AAR, Yu T, Demko ZO, et al. Long COVID brain fog and muscle pain are associated with<br>longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol. 2023;14. Accessed November 20, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147549
- 11. Lu S, Peluso MJ, Glidden DV, et al. Early Biological Markers of Post-Acute Sequelae of SARS-CoV-2 Infection. Published online July 16, 2023:2023.07.14.23292649. doi:10.1101/2023.07.14.23292649
- 12. Peluso MJ, Swank ZN, Goldberg SA, et al. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. MedRxiv Prepr Serv Health Sci. Published online December 29, 2023.2023.10.24.23297114. doi:10.1101/2023.10.24.23297114
- 13. Patterson BK, Francisco EB, Yogendra R, et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol. 2022;12:746021. doi:10.3389/fimmu.2021.746021

- 14 Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med N Y N. 2022;3(6):371-387.e9. doi:10.1016/j.medj.2022.04.001
- 15. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology. 2022;163(2):495-506.e8. doi: 10.1053/j gastro. 2022.04.037
- 16. Soni A, Herbert C, Pretz C, et al. Design and implementation of a digital site-less clinical study of serial rapid antigen testing to identify asymptomatic SARS-CoV-2 infection. J Clin Transl Sci. 2023;7(1):e120. doi:10.1017/cts. 2023.540
- 17. Rao A, Lin J, Parsons R, et al. Standardization and Comparison of Emergency Use Authorized COVID-19 Assays and Testing Laboratories. Published online November 8, 2023:2023.11.08.23297633. doi:10.1101/2023.11.08.23297633
- 2023:2023.11.08.23297633. doi:10.1101/2023.11.08.23297633 18. Soni A, Herbert C, Filippaios A, Soni Bethpainos A, Elippaining A, 1990, 1990, 1990.<br>Delta and Omicron Variants of SARS-CoV-2. Ann Intern Med. 2022;175(12):1685-1692. Delta and Omicron Variants of SARS-CoV-2. Ann Intern Med. 2022;175(12):1685-1692.
- doi:10.7326/M22-0760<br>19. Gentilini F, Turba ME, Taddei F, et al. Modelling RT-qPCR cycle-threshold using digital PCR data for implementing SARS-CoV-2 viral load studies. PLOS ONE. 2021;16(12):e0260884. doi: 10.1371/journal. pone. 0260884
- 20. Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020;71(15):793-798. doi:10.1093/cid/ciaa345 Infected Patients. Clin Infect Dis. 2020;71(15):793-798. doi:10.1093/cid/ciaa345
- 21. Vanderweele 13. Principles of companier selection. *Eur 3 Epidemiol.* 2019;34(3):211-219.<br>doi:10.1007/s10654-019-00494-6
- doi:10.1007/s10654-019-00494-6 22. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. Ann Intern Med. Published online January 22, 2021:M20-6976. doi:10.7326/M20-6976
- 23. Patients diagnosed with post-COVID conditions: an analysis of private healthcare claims using December 25, 2023. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-9918504887106676-pdf
- 24. Miyamoto S, Nishiyama T, Ueno A, et al. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection. Proc Natl Acad Sci. 2023;120(52):e2314808120. doi:10.1073/pnas.2314808120
- 25. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023;183(6):566-580. doi: 10.1001/jamainternmed. 2023. 0750
- 26. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in 20. Subramanian A, Niranian A, Niranian A, Nirang Covid in Long Corp. The risk factors for long Covid in the risk factors for long the state in the risk factors for long in the risk factors for long in the risk factors for non-hospitalized adults. Nat Med. 2022;28(8):1706-1714. doi:10.1038/s41591-022-01909-w

- 27. Jung J, Kim JY, Park H, et al. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in<br>Vaccinated and Unvaccinated Individuals. JAMA Netw Open. 2022;5(5):e2213606. doi:10.1001/jamanetworkopen. 2022.13606
- 28. Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022;28(7):1491-1500. doi: 10.1038/s41591-022-01816-0
- 29. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a SARS-COV-2 delta (B.1.617.2) variant in varianted and unvertimed individuals in the UK of prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183-195. doi:10.1016/S1473- 3099(21)00648-4<br>30. Ii H, Li Y, Liu J, Liu J, Han J, Yang L. Vaccination reduces viral load and accelerates viral clearance
- in SARS-CoV-2 Delta variant-infected patients. Ann Med. 2023;55(1):419-427. doi:10 1080/07853890 2023.2166681
- 31. Chen B, Julg B, Mohandas S, Bradfute SB, RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. Iqbal J, Zaidi M, eds. eLife. 2023;12:e8 persistence, reactivation, and mechanisms of long COVID. Iqbal J, Zaidi M, Cas. eLife. 2023,12:e86015.<br>doi:10.7554/eLife.86015 doi:10.7554/eLife.86015<br>32. Littlefield KM, Watson RO, Schneider JM, et al. SARS-CoV-2-specific T cells associate with
- inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLOS inflammation and reduced lung function in pullhonary post-acute sequalae of SARS-CoV-2. PLOS<br>Pathog. 2022;18(5):e1010359. doi:10.1371/journal.ppat.1010359 Pathog. 2022;18(5):e1010359. doi:10.1371/journal.ppat.1010359
- recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131(1). doi:10.1172/JCl140491 recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131(1). doi:10.1172/JCI140491
- 34. Herbert C, Manabe YC, Filippaios A, et al. Differential Viral Dynamics by Sex and Body Mass<br>Index During Acute SARS-CoV-2 Infection: Results from a Longitudinal Cohort Study. *Clin Infect Dis*. Published online November 16, 2023:ciad701. doi:10.1093/cid/ciad701
- 35. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020;10(10):e040129. doi:10.1136/bmjopen-2020-040129
- 36. Sylvester SV, Rusu R, Chan B, Bellows M, O'Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022;38(8):1391from Covid-10.1080/03007995.2022.2081454
- 1399. doi:10.1080<br>1399. doi:10995.2022.20079.20079.20079.2022.20 37. COVID-19 disease outcomes. Nature. 2020;588(7837):315-320. doi:10.1038/s41586-020-2700-3 COVID-19 disease outcomes. Nature. 2020;588(7837):315-320. doi:10.1038/s41586-020-2700-3
- 38. Agrawal S, Salazar J, Tran TM, Agrawal A. Sex-Related Differences in Innate and Adaptive<br>Immune Responses to SARS-CoV-2. Front Immunol. 2021;12. Accessed June 22, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2021.739757
- 39. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y  $2021.$  doi:1038/s41. doi:1038/s41. doi:1038/s41591-021-021-021-021-01292-y

- 40. Dursten May, Pennsylvan, Peyser ND, Pennsylvan Museum Museum Museum Progression Museum And Controller Museum Infect Dis. 2023;10(2):ofad047. doi:10.1093/ofid/ofad047 an Online Cohort Study. Open Forum Infect Dis. 2023;10(2):ofad047. doi:10.1093/ofid/ofad047
- 41. Qian Q, Fan L, Liu W, et al. Direct Evidence of Active SARS-Cov-2 Replication in the Intestine. Clin<br>Infect Dis. 2021;73(3):361-366. doi:10.1093/cid/ciaa925 Infect Dis. 2021;73(3):361-366. doi:10.1093/cid/ciaa925
- viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep. 2021;11(1):13308. viral RNA and SARS-Cov-2-specific IgA in patients with acute COVID-19. Sci Rep. 2021,11(1):13308.<br>doi:10.1038/s41598-021-92740-9
- doi:10.1038/s41598-021-92740-9<br>43. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens.  $JAMA$ . 2020;323(18):1843-1844. doi:10.1001/jama.2020.3786 JAMA. 2020;323(18):1843-1844. doi:10.1001/jama.2020.3786
- 44. Murphy SJ, Samson LW, Sommers BD. COVID-19 Antivirals Utilization: Geographic and<br>Demographic Patterns of Treatment in 2022. ASPE. Published December 23, 2022. Accessed January 10, 2024. https://aspe.hhs.gov/reports/covid-19-antivirals-utilization
- 10, 2024. https://aspe.hhs.gov/reports/covid-19-antivirals-utilization 45. Ma KC. Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated December 2022. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7225a3 December 2022. MMWR Morb Mortal Wkly Rep. 2023;72. doi:10.15585/mmwr.mm7225a3
- 44. Bowe B, Al-Aly Z. Acute and postacute sequence associated with SARS-Coverage with SARS-Coverage with SARS-Nat Med. 2022;28(11):2398-2405. doi:10.1038/s41591-022-02051-3

**(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.<br>It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2024.07.04.24309953;](https://doi.org/10.1101/2024.07.04.24309953) this version posted July 5, 2024. The copyright holder for this preprint

### **Figures:**

#### **Figure 1: Consort Diagram of Study Cohort**



**Legend**: **Consort Diagram of Study Cohort.** Of the 534 participants who tested positive for SARS-CoV-2 during the parent study, 200 received the long COVID survey and responded. For these analyses, participants were excluded if they were previously infected with SARS-CoV-2; a total of 28 participants self-reported a previous infection and were excluded for this reason. 172 participants with a total of 1455 observations were included in analyses, including 113 participants (65.7%) without long COVID and 59 participants (34.3%) with long COVID.



**Figure 2: Predicted Viral Load, Slope, and Time to Clearance by Number of Long COVID Symptoms** 

**Legend: Figure 2a shows mean predicted viral load each day starting from the day of peak viral load by number of long COVID symptoms.** Dark blue signifies individuals with 5+ long COVID symptoms, light blow shows individuals with 3-4 long COVID symptoms, grey indicates individuals with 1-2 long COVID symptoms, and the orange line includes individuals with no long COVID. Figure 2b displays the slope of viral clearance among participants with no long COVID, 1-2 long COVID symptoms, 3-4 long COVID symptoms, and 5+ long COVID symptoms. Higher slopes (closer to 0) are "flatter" than lower slopes (more negative). The blue boxes represent the interquartile range, and the navy line within the blue box displays the median slope for each group. Navy dots show the slope for each participant. Figure 2c shows predicted mean number of days from peak viral load to clearance calculating using the slopes of viral clearance, assuming clearance at a Ct value=40 (limit of detection). Days from peak viral load to clearance is a function of peak viral load and speed (slope) of clearance, so these estimates were calculated using maximum viral loads at the  $25<sup>th</sup>$  percentile, 50<sup>th</sup> percentile, and 75<sup>th</sup> percentile. Participants with long COVID with 3+ symptoms are shown in dark blue triangles, those with long COVID (with any number of symptoms) are shown in light blue circles, and participants without long COVID are in orange squares. Whiskers represent 95% confidence intervals.





**Legend: Probability of Long COVID by Viral Clearance and Sex.** Females are displayed in orange and males are displayed in blue. Whiskers show 95% confidence intervals. As slope increases, probability of long COVID increases among females. However, there is no significant increase in probability of long COVID as slope increases among males.

### **Figure 4: Association of Specific Long COVID Symptoms with Slope of Viral Clearance**



**Legend: Association of Specific Long COVID Symptoms with Slope of Viral Clearance**. Dotted black line shows a relative risk of 1. Black dots show the relative risk of each long COVID symptom from slope of viral clearance, adjusted for maximum number of symptoms during acute infection, age, and SARS-CoV-2 variant (Delta or Omicron). aRR: Adjusted Relative risk

### **Figure 5: Association Between Acute SARS-CoV-2 Symptoms and Risk of Long COVID**



**Legend: Association Between Acute SARS-CoV-2 Symptoms and Risk of Long COVID**. Dotted black line shows a relative risk of 1. Black dots show the adjusted relative risk of long COVID from acute SARS-CoV-2 symptoms, adjusted for age, BMI, and SARS-CoV-2 variant (Delta or Omicron). aRR: Adjusted Relative risk

#### **Tables:**

### **Table 1: Demographics of Cohort by Long COVID Status**



Data are presented as n (%).

<sup>a</sup>Comorbidities included: asthma, chronic kidney disease, COPD, cardiovascular disease, cancer, chronic lung disease, depression, diabetes, hypertension, immunocompromising conditions, serious mental health disorders (bipolar or schizophrenia), sickle cell disease, substance use or alcohol use disorders.





**Legend: Association of Slope of Viral Clearance with Number of Long COVID Symptoms.** Adjusted estimates are adjusted for maximum symptoms, age, and SARS-CoV-2 variant (Delta or Omicron). A unit-increase in slope was associated with a 4.97 times higher risk of having 5+ long COVID symptoms, adjusted for maximum symptoms during acute SARS-CoV-2 infection, age, and variant.



**Table 3: Association between Number of Acute COVID-19 Symptoms and Risk of Long COVID** 

\*Adjusted for age, BMI, and variant (Delta or Omicron)